Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
University of Oxford
ClinicalTrials.gov Identifier:
NCT01252953
First received: November 24, 2010
Last updated: April 16, 2014
Last verified: April 2014